前沿生物(688221) - 2024 Q4 - 年度业绩预告

Financial Projections - The company expects to achieve an operating revenue of approximately CNY 125 million to CNY 130 million in 2024, representing a year-on-year increase of 9.41% to 13.79%[4] - The net loss attributable to shareholders is projected to be between CNY 182 million and CNY 220 million, a reduction in loss of approximately CNY 108.96 million to CNY 146.96 million compared to the previous year[4] - The company anticipates a net loss excluding non-recurring gains and losses of approximately CNY 315 million to CNY 354 million, a decrease in loss of about CNY 0.596 million to CNY 3.96 million[4] Research and Development - Research and development expenses are expected to be around CNY 134 million to CNY 139 million, a year-on-year decrease of 35.12% to 37.45%[8] - The company has received approval for a Phase II clinical trial for the new indication of its product Aikening® for "immune reconstitution in HIV-1 infected patients" from the National Medical Products Administration[12] - The company has submitted a generic drug marketing application for the FB3002 project (pain relief adhesive) to the National Medical Products Administration[13] Market Expansion and Partnerships - The company has expanded its coverage to over 300 HIV treatment hospitals and more than 200 DTP pharmacies across 30 provinces and municipalities in China[10] - The company has established a commercial partnership for the FB4001 project (teriparatide injection generic drug) in the U.S. market, aiming for commercialization by 2025[13] - The company continues to strengthen its market penetration and commercialization efforts for Aikening®, which has been included in the National Medical Insurance Directory for 2024[9] Financial Reporting - The financial data presented is preliminary and has not been audited by a registered accountant, with the final figures to be disclosed in the audited 2024 annual report[14]